AlloCyte Pharmaceuticals

Executive Summary

AlloCyte Pharmaceuticals AG is a privately held Swiss biotechnology company headquartered in Basel, dedicated to advancing allogeneic cell therapies for immunology and oncology indications. Founded in 2016, the company leverages proprietary platforms to develop off-the-shelf cell products designed to overcome the limitations of autologous treatments, such as high cost and manufacturing complexity. While specific pipeline details are not publicly disclosed, the company is likely focused on T-cell or NK-cell therapies targeting autoimmune diseases and hematologic malignancies. With a strong R&D presence in Switzerland’s biotech hub, AlloCyte is positioned to capitalize on the growing demand for scalable, cost-effective cell therapies. The company remains in a pre-commercial stage, with no reported funding rounds or partnerships to date, suggesting an early development phase. Given the lack of publicly available clinical data, the investment thesis hinges on the potential of its proprietary technology and the execution of its development strategy.

Upcoming Catalysts (preview)

• Q2 2027First clinical data readout from lead allogeneic cell therapy program30% success
• Q4 2026Series A financing round to advance pipeline60% success
• H1 2027Research partnership with academic or pharma partner for platform validation40% success